Refusal of orphan designation for the treatment of autosomal dominant polycystic kidney disease

sodium ascorbate / menadione sodium bisulfite


On 21 July 2014, the Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on the orphan designation application for sodium ascorbate and menadione sodium bisulfite for the treatment of autosomal dominant polycystic kidney disease. A negative decision was issued by the European Commission on 11 December 2014.

The sponsor applied for orphan designation on the basis of the seriousness and the rarity of the condition.

The negative opinion was based on the following reasons:

  • The sponsor calculated the prevalence of autosomal dominant polycystic kidney disease on the basis of a limited number of publications, and the methodology used to estimate the prevalence was not adequately justified.
  • The COMP noted that the prevalence of the genotype for the disease is higher than 5 in 10,000 people in the European Union and that the sponsor could not prove that the disease itself does not have a prevalence higher than this figure. 5 in 10,000 people is the maximum allowable prevalence for orphan designation.

Requests for designation as an orphan medicinal product are made for investigational products. Absence of orphan designation does not preclude the development of this product, including its use in clinical trials. A marketing authorisation can still be obtained if quality, safety and efficacy are demonstrated.

Key facts

Active substance
  • sodium ascorbate
  • menadione sodium bisulfite
Intended use
Treatment of autosomal dominant polycystic kidney disease
Orphan designation status
EU designation number
Date of refusal of designation
JJGConsultancy Ltd
Sherston House
High Street
Somerset BA4 6HZ
United Kingdom
Tel. +44 (0)1749 838886
Fax +44 (0)1749 838887

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating